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Abstract
Background: Chronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has
been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic
alterations may appear in CD34+ hematopoietic progenitors. However, the presence of both chromosomal
aberrations and gene mutations in CD34+ cells from the same patients has not been explored.
Methods: Amplicon-based deep next-generation sequencing (NGS) studies were carried out in magnetically
activated-cell-sorting separated CD19+ mature B lymphocytes and CD34+ hematopoietic progenitors (n = 56) to study
the mutational status of TP53, NOTCH1, SF3B1, FBXW7, MYD88, and XPO1 genes. In addition, ultra-deep NGS was
performed in a subset of seven patients to determine the presence of mutations in flow-sorted CD34+CD19− early
hematopoietic progenitors. Fluorescence in situ hybridization (FISH) studies were performed in the CD34+ cells from
nine patients of the cohort to examine the presence of cytogenetic abnormalities.
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Results: NGS studies revealed a total of 28 mutations in 24 CLL patients. Interestingly, 15 of them also showed the
same mutations in their corresponding whole population of CD34+ progenitors. The majority of NOTCH1 (7/9) and
XPO1 (4/4) mutations presented a similar mutational burden in both cell fractions; by contrast, mutations of TP53 (2/2),
FBXW7 (2/2), and SF3B1 (3/4) showed lower mutational allele frequencies, or even none, in the CD34+ cells compared
with the CD19+ population. Ultra-deep NGS confirmed the presence of FBXW7, MYD88, NOTCH1, and XPO1 mutations
in the subpopulation of CD34+CD19− early hematopoietic progenitors (6/7). Furthermore, FISH studies showed the
presence of 11q and 13q deletions (2/2 and 3/5, respectively) in CD34+ progenitors but the absence of IGH
cytogenetic alterations (0/2) in the CD34+ cells. Combining all the results from NGS and FISH, a model of the
appearance and expansion of genetic alterations in CLL was derived, suggesting that most of the genetic events
appear on the hematopoietic progenitors, although these mutations could induce the beginning of tumoral cell
expansion at different stage of B cell differentiation.
Conclusions: Our study showed the presence of both gene mutations and chromosomal abnormalities in early
hematopoietic progenitor cells from CLL patients.
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Chromosomal abnormality
Background
Chronic lymphocytic leukemia (CLL) is characterized by
the clonal proliferation and accumulation of neoplastic
B lymphocytes in the blood, bone marrow, lymph nodes,
and spleen [1, 2]. Immunophenotype analysis of CLL
cells shows expression of CD5 T cell antigen as well as
CD19, CD20, and CD23 B cell surface antigens [3]. In
molecular terms, CLL is defined by the presence of
chromosomal abnormalities (11q-, +12, 13q-, 17p-) that
play an important role in CLL prognosis [4]. The muta-
tional status of the immunoglobulin heavy chain (IGHV)
is also considered a prognostic marker in CLL [5, 6]. Re-
cently, the development of next-generation sequencing
(NGS) techniques has enabled mutations to be identified
in novel target genes in CLL [7, 8], and mutations in
some drivers such as NOTCH1, SF3B1, TP53, and
MYD88 genes have been shown to have a prognostic
impact in CLL patients [9–11].
The cellular origin of this disease remains controver-
sial [12–14]. Recent studies have reported that CLL
pathogenesis may start at a previous maturational cell
stage, or even in hematopoietic stem cells (HSCs). Fluor-
escence in situ hybridization (FISH) studies showed that
+12 and 13q- abnormalities are present in CD34+CD19
− cells, suggesting that these common chromosomal ab-
normalities could appear in HSCs [15, 16]. Interestingly,
xenotransplantation studies reported that HSCs from
CLL patients were able to reproduce the CLL phenotype
in murine models [17]. In addition, CLL mutations may
appear in HSCs, supporting the idea that CLL patho-
genic events occur at an early stage of the hematopoietic
process [18].
Taking the previous studies in this field into account,
it is well known that chromosomal abnormalities as well
as gene mutations are important events in CLL
pathogenesis [19]. However, it is still not clear which
genetic events are related with the origin of the disease
and when these alterations occur and have a functional
impact inducing tumoral cell expansion during B cell
differentiation. For these reasons, in this study, chromo-
somal abnormalities and gene mutations in hematopoietic
progenitors were analyzed, showing that the whole popu-
lation of CD34+ progenitors, even at the level of CD34
+CD19−, are already affected at genetic level in CLL pa-
tients. In particular, mutations of FBXW7, MYD88,
NOTCH1, and XPO1 as well as 11q and 13q deletions
were detected in CD34+ progenitors. By contrast, the ori-
gin of TP53 and SF3B1 mutations and IGH alterations
could take place at a later maturational stage. Apart from
B lymphocytes, some of these genetic alterations were
also observed in other mature cell fractions (T lym-
phocytes and monocytes) derived from HSCs.
Integrating all these results, a pattern of appearance
and expansion of these genetic events during B-CLL
cell differentiation was suggested.
Methods
Patients
Samples were collected from the bone marrow (BM) of
56 CLL patients. CLL was diagnosed according to the
World Health Organization (WHO) classification [20]
and the National Cancer Institute (NCI) Working Group
criteria [21]. A complete immunophenotypic analysis of
all cases was carried out by flow cytometry. The main
biological features of the CLL patients are summarized
in Additional file 1: Table S1.
Cell isolation and DNA extraction
Total CD34+ progenitor cells and CD19+ B cells were
separately isolated from BM samples of CLL patients
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using magnetically activated cell sorting (MACS) CD34
and CD19 MicroBeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany), respectively, according to the manufac-
turer’s instructions. The workflow followed consisted of
three steps: first, the isolation of the whole population of
CD34+ cells (including CD34+CD19− early progenitors
and CD34+CD19+ pro-B cells) from the total BM
mononuclear cells, followed by the selection of CD19+
cells from the CD34 negative cell fraction resultant from
the first step. Cell purities were determined by flow cy-
tometry, being greater than 90 and 98% for each CD34+
and CD19+ cell fractions, respectively.
In addition, fluorescence-activated cell sorting (FACS)
(BD Biosciences, San Jose, CA, USA) was carried out in
order to sort the specific subpopulation of CD34+CD19
− cells as well as other mature cells such as CD19+ B
lymphocytes, CD3+ T lymphocytes, and CD14+ mono-
cytes, from peripheral blood (PB) samples in a second
time point of the disease of seven CLL patients. Samples
were stained with FITC anti-CD14 (Beckman Coulter),
phycoerythrin (PE) anti-CD3 (Becton Dickinson), PE-
Cy7 anti-CD19 (Immunostep S.L.), PerCP-Cy5.5 anti-
CD45 (BioLegend), and allophycocyanin (APC) anti-
CD34 (Becton Dickinson). Purities were greater than
98% in all cell fractions (Additional file 1: Figure S1).
Genomic DNA was extracted from the different cell
populations by column-based purification (AllPrep DNA/
RNA Mini Kit, Qiagen, Hilden, Germany) following the
manufacturer’s instructions.
Next-generation sequencing
NGS was performed in CD19+ B lymphocytes from all
56 CLL patients. Amplicon-based NGS was carried out
on a GS Junior platform (454 Life Sciences, Branford,
CT, USA) using the 454 Titanium Amplicon system
(Roche Applied Science, Penzberg, Germany) [22] to
investigate the mutational status of TP53 (exons 4–11),
NOTCH1 (exons 33–34), SF3B1 (exons 10–16), FBXW7
(exons 8–12), MYD88 (exons 4–5), and XPO1 (exons
14–15) in CD19+ cells. The mutations identified in
CD19+ cells were further analyzed in the corresponding
whole population of CD34+ progenitors in order to
determine whether the same mutations were present in
an earlier step than B mature cells. Primer information,
PCR conditions, and oligonucleotide design used in pre-
vious studies were adopted [23, 24]. The oligonucleotide
was designed as part of the work of the IRON-II net-
work. Sequencing data were obtained and analyzed using
the GS Data Analysis Software package (Roche Applied
Science, Penzberg, Germany) and the Sequence Pilot
software for genetic analysis (JSI Medical Systems,
Ettenheim, Germany). Mutations detected in more than
2% of bidirectional reads per amplicon in CD19+ cells
and in more than 10% in CD34+ cells were accepted
taking into account sequencing coverage (median 980
reads; coverage range 304–9387-fold) [25, 26] and MACS
purities from each cell population (98% for CD19+ and
90% for CD34+ cells).
Ultra-deep NGS
To define if the mutations appeared in the specific sub-
population of CD34+CD19− cells and other mature popu-
lations derived from the hematopoietic progenitors,
mutated target regions were sequenced by ultra-deep
NGS, using an Illumina platform, in flow-sorted CD34
+CD19−, CD19+, CD3+, and CD14+ cell populations
from seven CLL patients. NGS analysis was performed on
MiSeq (Illumina, San Diego, CA, USA) using genomic
DNA from peripheral blood flow-sorted CD19+ B lym-
phocytes, CD34+CD19− early progenitors, CD3+ T lym-
phocytes, and CD14+ monocytes. DNA was amplified
using REPLI-g Mini Kit (Qiagen, Hilden, Germany). Tar-
get PCRs were performed using exon-specific primers
(Additional file 1: Table S2). The experimental design and
reaction conditions followed the manufacturer’s recom-
mendations. Briefly, PCR products were purified with
High Pure PCR Product Purification Kit (Roche Diagnos-
tics, Mannheim, Germany) and quantified using Qubit
dsDNA HS Assay Kit (Life Technologies, Waltham, MA,
USA). The purified amplicons were pooled to a total
amount of 50 ng. The indexed paired-end library was pre-
pared with NEBNext Ultra II DNA Library Prep kit for
Illumina (NEW ENGLAND BioLabs) and sequenced
using MiSeq (median coverage 4399 reads; range 1491–
8614-fold). In order to verify the accuracy of the variant
allele frequency (VAF), non-amplified DNA was se-
quenced in all cases with available material, finding no
differences comparing to the VAFs obtained with a
previous step of whole-genome amplification.
In-house pipeline was performed to analyze sequen-
cing data. Sequencing reads were aligned to the refer-
ence genome GRCh37/hg19 using BWA-0.7 [27]. The
alignments were refined with tools of the GATK-3.5
suite [28], and the variants were called according to
GATK Best Practice recommendations [29, 30]. Finally,
ANNOVAR was used for annotations and prediction of
functional consequences [31].
The variant detection was set at 2% taking into account
the sequencing coverage and the purities from all sorted
cell fractions (more than 98%). Mutations detected at low
frequencies (< 15%) by ultra-deep NGS were also validated
using 454 Titanium Amplicon System (Roche Applied
Science, Penzberg, Germany) (median 1712 reads; cover-
age range 1277–2638-fold) [23, 24].
Fluorescence in situ hybridization
Interphase FISH was carried out in B cells from 56 BM
samples using commercially available probes: 11q22/
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ATM, 12p11.1-q11 (alpha satellite), 13q14, 14q32/IGH,
and 17p13/TP53 (Vysis/Abbott Co, Abbott Park, IL,
USA). Dual-color FISH using differently labeled control
and test probes was implemented following the methods
previously described [32]. FISH was also performed in
the CD34+ cells of a group of nine CLL patients to as-
sess the presence of the cytogenetic alterations identified
in the corresponding CD19+ cell fraction. Samples were
placed in a Cytospin cytocentrifuge (Thermo Scientific,
Waltham, MA, USA) to concentrate the low number of
cells. Signal screening was performed in at least 200 cells
with well-delineated fluorescence spots. According to
our cut-off standards, a score ≥ 10% was considered
positive in all cases.
Statistical analysis
Statistical analyses were performed using IBM SPSS for
Windows, Version 22.0 (IBM Corp., Armonk, NY, USA).
Time to first therapy (TFT) and overall survival (OS)
were analyzed on the date of the initial FISH study. Only
leukemia-related deaths were considered when analyzing
OS. The chi-square test was used to assess associations
between categorical variables; continuous variables were
analyzed with the Mann-Whitney U test. Variables sig-
nificantly associated with TFT and OS were identified by
the Kaplan-Meier method, and the curves of each group
were compared with the log-rank test. Results were
considered statistically significant for values of p < 0.05.
Results
Mutations of driver genes are already present in
hematopoietic progenitor cells of CLL patients
Sequencing studies revealed a total of 28 mutations in
24 of the 56 (42.9%) CLL patients. Most of these patients
(20/24; 83.3%) showed a single mutation in the analyzed
genes, and four of them had two mutations in different
genes (ID-34, ID-49, ID-50, and ID-53) (Table 1). The
most frequently mutated gene was NOTCH1 (23.2%),
followed by XPO1 (8.9%), SF3B1 (7.1%), FBXW7 (5.4%),
TP53 (3.6%), and MYD88 (1.8%) (Fig. 1). All of them
have been previously reported as mutations in the COS-
MIC database (http://cancer.sanger.ac.uk/cosmic). All
patients with mutations in NOTCH1 carried the same al-
teration (p.P2514Rfs*4), while XPO1 mutations corre-
sponded to a previously reported gain-of-function
mutation (p.E571K) in all cases. In addition, all SF3B1,
FBXW7, TP53, and MYD88 mutations analyzed were
missense mutations.
In order to assess whether the mutations identified in
CD19+ cells were also present in a previous step during
B cell differentiation, the mutated target regions were
analyzed by NGS in the total CD34+ cells. Strikingly, 15/
24 patients (62.5%) showed the same mutations in their
corresponding CD34+ cells (Table 1). The allele
frequencies of mutations observed in a higher percent-
age than 10% of both CD19+ and CD34+ cell popula-
tions were compared calculating a CD19/CD34 ratio
based on the percentage of mutated cells from each cell
population. The cut-off CD19/CD34 ratio of 2.5 revealed
two different mutational patterns between both cell frac-
tions: “maintained” (ratio < 2.5) and “decreased” (ratio
≥ 2.5). Specifically, most of the mutations in NOTCH1
(7/9) and XPO1 (4/4) presented a similar mutational
burden in both CD19+ and CD34+ cell fractions
(Table 1; Fig. 2a). By contrast, alterations in TP53 (2/2),
FBXW7 (2/2), and SF3B1 (3/4) showed a clearly lower
percentage or even an absence in the CD34+ cells with
respect to the corresponding mature B lymphocytes
(Table 1; Fig. 2b).
In a further step to assess if the mutations observed in
the whole population of CD34+ progenitor cells appeared
in the subpopulation of CD34+CD19− early hematopoietic
progenitors, ultra-deep NGS was performed. Flow-sorted
CD34+CD19− cells in a second time point from PB of a
subset of patients were sequenced, confirming that six out
of seven mutations—validated on the B lymphocytes from
this time point—were also detected in the hematopoietic
progenitor cells (Table 2). Particularly, MYD88, NOTCH1,
XPO1, and FBXW7 mutations were observed in CD34
+CD19− cells. On the other hand, SF3B1 mutation was not
observed in the CD34+CD19− cells from patient ID-50.
Apart from this, this patient, who was treated before the
second time point, did not show FBXW7 mutation in its B
lymphocytes.
Distinctive pattern of distribution of CLL driver mutations
along hematopoietic lineages
Ultra-deep NGS revealed that gene mutations can be also
present in other mature cells derived from hematopoietic
stem cells. Thus, the same mutations detected in CD19+ B
lymphocytes as well as in their corresponding CD34+CD19
− progenitors were also detected in a very low percentage
of CD3+ cells and in CD14+ cells in some CLL patients
(Table 2). Specifically, ID-13 and ID-36 patients, who har-
bored MYD88 and FBXW7 mutations, respectively, also
presented these mutations in both CD3+ and CD14+ cell
populations. Moreover, ID-57 (FBXW7 mutated) showed
the mutation on its monocytes whereas ID-37 (XPO1 mu-
tated) carried the same alteration on the T lymphocytes.
Interestingly, when the allele frequencies from all cell
populations were compared, different patterns could be
observed. First, MYD88 and NOTCH1 mutations (ID-13
and ID-42) appeared in > 10% of CD34+CD19− cells. In
case of XPO1 and FBXW7, their mutations also appeared
in CD34+CD19− cells but in a relatively low percentage
(< 5%). In addition, NOTCH1 mutations only appeared
on the hematopoietic progenitors and the mature B
lymphocytes whereas FBXW7 and MYD88 mutations
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seemed to appear in all the sequenced cell fractions, af-
fecting even myeloid lineage and T lymphoid lineage.
On the other hand, patient ID-50 did not present its
SF3B1 mutation in the CD34+CD19− nor the T lympho-
cytes and monocytes (Table 2).
All these mutations detected at low frequencies
(< 15%) in CD34+CD19−, CD3+, and CD14+ cells were
also validated by 454 sequencing when material was
available (Additional file 1: Table S3).
Several cytogenetic abnormalities are detected in a
previous developmental stage of the mature B
lymphocytes of CLL patients
FISH studies revealed a total of 39/56 (69.6%) CLL
patients with cytogenetic abnormalities in B lympho-
cytes. Specifically, 13q deletion was the most common
aberration in our cohort (46.3%), followed by trisomy 12
(17%), 11q deletion (11.3%), IGH alterations (9.3%), and
17p deletion (1.9%) (Additional file 1: Table S1).
Fig. 1 Cytogenetics and molecular characteristics of CD19+ and CD34+ cells. In the heatmap, rows correspond to the indicated alterations and
each column represents individual CLL samples. Color-coded based on the gene and cytogenetic status (dark gray, altered; light gray, not-altered;
white, not analyzed). For IGHV status: dark gray, unmutated; light gray, mutated. *Only mutations with VAF > 10% were considered for MACS
isolated CD34+ cells considering the purities obtained. **Mutations in CD34+CD19− cells were assessed by ultra-deep NGS, considering mutations
with VAF > 2%, taking into account the cell purities obtained from FACS sorting
Fig. 2 Mutational burden in CD19+ (dark gray) and CD34+ (light gray) cells from CLL patients. a NOTCH1 and XPO1 mutational burdens are
similar in CD34+ and CD19+ cell populations. b TP53, FBXW7, and SF3B1 mutational burdens were lower in the CD34+ cell population
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To asses if the chromosomal abnormalities where
also present in a previous step of the B cell differen-
tiation, FISH analyses were performed in the whole
population of CD34+ cells of a subset of patients (n
= 9) (Fig. 1). Interestingly, these analyses revealed
that five of nine CLL patients with cytogenetic alter-
ations in mature B lymphocytes showed the same
chromosomal aberration in the CD34+ cells, al-
though at a lower percentage than in CD19+ cells
(Table 3). Specifically, both CLL patients with 11q-
and three of five patients with 13q- showed the
same cytogenetic alteration in the corresponding
CD34+ cells. By contrast, IGH abnormalities identi-
fied by FISH in two CLL patients (ID-02 and ID-17)
were not identified in their corresponding CD34+
cells. Apart from these alterations, the only CLL pa-
tient with +12, whose CD34+ cells were analyzed by
FISH, did not have this trisomy in their correspond-
ing progenitor cells.
Patients with multiple genetic alterations show a
hierarchy in the appearance of these events
The combination of NGS and FISH data revealed that
two patients presented both mutations and chromo-
somal abnormalities (Table 3). The first case (ID-02)
had an IGH alteration and a NOTCH1 mutation in
the CD19+ cells. However, FISH studies and NGS
analysis of CD34+ progenitors revealed that the
NOTCH1 mutation was the only genetic event. The
second case (ID-21) showed two chromosomal abnor-
malities (11q- and 13q-) and an XPO1 mutation.
These three alterations were also observed in the
CD34+ cells, although 11q- and 13q- were present in
a higher percentage of cells (72 and 49%) than the
XPO1 variant (30%).
Four cases showed a co-occurrence of mutations in
two different genes. Thus, two patients (ID-34 and ID-
49) carried mutations in NOTCH1 and XPO1, present in
both CD19+ and CD34+ cell fractions, with NOTCH1
Table 2 Mutations in CD19+, CD34+CD19−, CD3+ and CD14+ PB cell populations identified by ultra-deep NGS
Time point 1; bone
narrow
Time point 2: peripheral blood
Patient ID IGHV mutation
status
Mutated gene AA change %mut
CD19
%mut CD34 %mut CD19+ %mut CD34+CD19− %mut CD3+ %mut CD14+
13 Mutated MYD88 p.M232T 36 22 23.1 12.2 2.6 7.7
31 Mutated NOTCH1 p.P2514Rfs*4 4 < 10 15.3 2.1 0 0
36 Mutated FBXW7 p.R465L 39 < 10 3.2 3.0 2.7 3.6
37 Unmutated XPO1 p.E571K 51 38 53.0 3.0 3.0 0.4
42 Unmutated NOTCH1 p.P2514Rfs*4 5.25 < 10 33.0 12.9 0 0.6
50 Unmutated SF3B1 p.R625H 21 < 10 15.0 1.0 0.1 0.1
50 Unmutated FBXW7 p.G423V 8 < 10 0 0 0 0
57 Mutated FBXW7 p.R465H 42 13 46.5 2.4 0.8 2.6
The cut-off set for the second time point was 2% (bold) provided that our FACS purities were higher than 98% in all cases for all cell populations
Table 3 FISH analysis in CD34+ cell populations of nine patients



















2 Unmutated IGH alt 80 No – NOTCH1 51 31
15 Mutated 13q- 65 Yes 25 –
16 Unmutated +12 22 No – –
17 Mutated IGH alt 54 No – –
21 Unmutated 11q- 64 Yes 49 XPO1 39.5 31
21 13q- 93 Yes 72
23 Unmutated 11q- 79 Yes 36 –
26 Mutated 13q- 67 Yes 46.5 –
27 Mutated 13q- 86 No – –
29 Mutated 13q- 25 No – –
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always being the dominant clone with respect to XPO1
(52 vs. 25%; 55 vs. 31%). The patient ID-50 harbored
mutations in SF3B1 and FBXW7, which occurred at a
much lower or null percentage in the CD34+ progeni-
tors (21 vs. 2.5%; 8 vs. 0%). Finally, patient ID-53 had
mutations in SF3B1 and TP53 in a low percentage of
CD34+ cells compared with that in CD19+ B lympho-
cytes (43 vs. 14%; 41.5 vs. 16.5%).
Clinical and biological correlations with genetic
alterations in CD34+ cells in CLL patients
The clinical impact of the presence of mutations in the
whole population of CD34+ cells was explored. The pres-
ence of mutations in the whole CD34+ cell population
was associated with an unmutated IGHV status (p = 0.003)
and high levels of serum β2 microglobulin (p = 0.011)
(Additional file 1: Table S4). Interestingly, patients with
mutations in their CD34+ progenitors also showed shorter
OS (p = 0.01) (Additional file 1: Figure S2A) than patients
without mutations in this cell fraction. In addition, pa-
tients harboring mutations in NOTCH1, SF3B1, and TP53
in their hematopoietic progenitors presented a shorter
TFT (p = 0.028) (Additional file 1: Figure S2B). Moreover,
comparing the two mutational patterns identified in the
CD34+ cells fraction, the mutations maintained on the
CD34+ progenitors were significantly associated with the
absence of trisomy 12 in the B lymphocytes (p = 0.014)
(Additional file 1: Table S5).
Comparing the mutational burden in the CD34+ frac-
tion between BM samples collected before and after
treatment revealed no significant differences (p = 0.605).
Four patients who received treatment before the extrac-
tion of the BM relapsed. Interestingly, all of them
showed mutations in the CD34+ progenitors with a
similar mutational burden as the corresponding CD19+
B lymphocytes (Additional file 1: Table S6).
Discussion
Our data provide evidence of the presence of mutations
and chromosomal abnormalities in early hematopoietic
progenitors in BM samples of CLL patients. These re-
sults shed light on the cell of origin of CLL in a previous
developmental stage to mature B cells, demonstrating
CLL patients can also show genetic events in the CD34+
hematopoietic progenitors. These results are consistent
with the findings of two recent studies [17, 18]. MACS
isolation was performed on the whole population of
CD34+ cells including CD34+CD19+ pro-B cells. A pre-
vious study has reported that the pro-B cell population
is larger in the bone marrow of CLL patients than in
healthy donors (mean range of 18% pro-B cells in the
total bone marrow CD34+ cell count, exceeding 30% in
some cases) [17]. This suggests that the patients who
presented a mutational burden of < 30% in the CD34+
cell population may only harbor the mutation in CD34
+CD19+ pro-B cells, rather than in the early
hematopoietic progenitors. It is of particular note that
10 out of 15 patients with mutations in the whole popu-
lation of CD34+ cells had mutational rates of > 30%,
suggesting that these mutations not only appear in the
pro-B cells, but also at earlier maturational stages of B
cell differentiation (CD34+CD19− progenitors). In order
to assess this hypothesis, we could perform ultra-deep
NGS studies of flow-sorted CD34+CD19− cells using PB
samples in a small subset of patients within the main co-
hort, detecting that all the mutations, except to one,
were already present in this cellular fraction. Therefore,
these results confirmed that mutations on CLL driver
genes could occur in early hematopoietic progenitor
cells of these patients. In particular, our sequencing re-
sults suggest that mutations in NOTCH1, MYD88,
FBXW7, and XPO1 may appear in CD34+CD19− cells
whereas TP53 and SF3B1 mutations could appear in a
later stage of B cell differentiation. As far as we are con-
cerned, these results were demonstrated for the first
time in fresh hematopoietic progenitor cells without
having been cultured.
As these driver mutations have been detected in early
hematopoietic progenitors of some CLL patients, we hy-
pothesized that these alterations can affect hematopoietic
lineages other than B cells. As it was previously reported,
some mutations in well-known CLL drivers can also ap-
pear on a low percentage in other mature cell fractions as
CD3+ T lymphocytes and/or CD14+ monocytes [18].
In order to determine the stage of B cell differentiation
in which these mutations induced an expansion of the
tumoral cell population, first, the mutational burdens in
CD19+ mature B lymphocytes and CD34+ progenitors
were compared. Since the mutational burden in CD34+
cells with NOTCH1 mutations was as high as that ob-
served in CD19+ cells in most of the cases, it could be
hypothesized that mutations in this gene induced an ex-
pansion of the CLL hematopoietic progenitors. Indeed,
ultra-deep NGS studies confirmed this in patient ID-42
who had NOTCH1 mutation in more than 10% of CD34
+CD19− cells. Moreover, every XPO1 mutation observed
in our cohort was present in the CD34+ progenitors and
the mutational burden remained similar in both cellular
fractions. However, the percentage of XPO1 mutations
in the CD34+ cells exceeded 30% in very few cases, sug-
gesting that these mutations could be enriched at an
intermediate B cell stage as CD34+CD19+ pro-B cells.
On the other hand, the mutational burdens of TP53,
SF3B1, and FBXW7 were considerably lower in the
CD34+ cell population. Although SF3B1 mutation was
not detected in CD34+CD19− cells, suggesting it as a
late event in B-CLL differentiation, one out of four
SF3B1 mutated patients (ID-43) carried a mutation in a
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high percentage of the whole population of CD34+ pro-
genitors, similar to results from a previous study [18].
Besides this, alterations in this gene have been also re-
ported in CD34+ cells of patients with myeloid malig-
nancies [33]. Therefore, it should be essential to study
larger cohorts of CLL patients in order to determine
what type of SF3B1 mutations occur in HSCs of CLL pa-
tients and functional studies to assess the differences be-
tween “CLL-HSCs SF3B1 mutated” and “MDS-HSCs
SF3B1 mutated.”
Focusing on the presence of cytogenetic abnormalities
in CD34+ cell populations in our cohort, 11q- and 13q-
appeared in the CD34+ progenitors at high percentages,
as reported previously [15, 16], supporting the hypothesis
that these chromosomal aberrations could be an early
event in CLL [8]. By contrast, IGH alterations were not
present in any of the CD34+ hematopoietic progenitors.
Previous case report studies have yielded similar results
[34, 35], suggesting that IGH alterations occur in an ad-
vanced stage of the lymphocyte maturation process.
The analysis of patients with more than one genetic al-
teration allowed us to define a hierarchy of the appear-
ance of these genetic events. When IGH alterations and
the NOTCH1 mutation are present in the same patient
(ID-02), it is clear that the NOTCH1 mutation is an earl-
ier step than the IGH alteration during B cell differenti-
ation. Moreover, when 11q-, 13q-, and XPO1 mutations
are present in the same patient (ID-21), they all appear
in the CD34+ progenitors. However, 11q- and 13q- are
certainly present at a higher allele frequency than the
mutational load of XPO1, suggesting that cells with 11q-
and 13q- were expanded in an earlier stage than the
XPO1 mutation in the pathogenesis of the disease [8].
Specifically, the dominant clone in the two cases with a
double mutation in NOTCH1 and XPO1 (ID-34 and ID-
49) was always NOTCH1 rather than XPO1. Therefore,
since XPO1 is still present in a small part of the CD34
+CD19− cell population and greatly enriched on the total
CD34+ fraction, we may consider that cells carrying XPO1
mutations are expanded in an intermediate event of B-
CLL differentiation, given the previous possible events
such as 13q- and 11q- abnormalities or MYD88 and
NOTCH1 mutations. Taking into account all these results,
a model of the appearance of genetic events during the
hematopoiesis in CLL has been suggested (Fig. 3). How-
ever, as some of these genetic alterations were observed in
few cases, it would be interesting to sequence all cell frac-
tions in larger cohorts of patients.
The prognostic impact of gene mutations and chromo-
somal abnormalities in CLL has been well characterized in
several studies of large cohorts of patients [4, 9, 23, 36].
TP53, NOTCH1, and SF3B1 are described as poor prognos-
tic mutations [10, 37–40]. The prognostic impact of the
presence of mutations in CD34+ cells from CLL patients
Fig. 3 Schematic model of events in hematopoiesis in CLL patients. Red gene names indicate the moment of appearance of mutations. Black
names indicate the presence of a gene mutation in an specific cell population whereas underlined black gene names indicate the moment of
expansion of tumoral cells harboring these gene mutations during B-CLL differentiation
Quijada-Álamo et al. Journal of Hematology & Oncology  (2017) 10:83 Page 9 of 11
has been assessed for the first time in this study, showing
that CLL patients harboring mutations in the
hematopoietic progenitors showed worse prognosis. It is es-
sential to achieve a better understanding of these results
since only six genes were analyzed in our study, whereas a
CLL exome exhibits an average of 20 mutations [8, 10].
Therefore, further studies analyzing the whole exome in lar-
ger cohorts should be performed in order to accurately de-
fine their impact. In addition, conventional CLL therapies
may not be able to eradicate or reduce the malignant CD34
+ CLL clone and may be responsible for the relapse of pa-
tients bearing mutations in these cells. Given that these
therapies seem not to have a clear effect on CD34+ CLL
cells, allogeneic stem cell transplantation could be an op-
tion for overcoming the challenges that may arise from
CD34+ cell treatment [41].
Conclusions
Our data show that recurrent CLL chromosomal abnor-
malities and gene mutations are present not only in ma-
ture B lymphocytes but also in hematopoietic progenitors.
Although CLL is a clonal mature B cell disease, our results
provide strong evidence that CLL may originate in the
early stages of hematopoiesis. Both chromosomal alter-
ations and point mutations are highly relevant to the dis-
ease pathogenesis, with a clinical impact as soon as they
appear. To the best of our knowledge, our study is the first
to analyze both genetic events in different cellular frac-
tions of the same patients by NGS and FISH. It provides
us with a broader understanding of CLL initiation and de-
velopment, opening up possibilities for future therapies.
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